What We Look For

Investment and Partnership Criteria


We seek to partner with innovative healthcare IT and healthcare technology-enabled services. BMP partners with highly capable entrepreneurs whose talents and experience will translate into successful and meaningful companies. BMP makes investments in both early and growth stage businesses.

Growth Fund Investment Criteria:

  • Experienced “A” level management teams with a record of demonstrable success
  • Product or service offering with a sustainable competitive advantage
  • A large addressable market and growing rapidly
  • $1-20 million in revenue
  • Profitable or achieving profitability within 18 months
  • <$50 million enterprise values

Founders Fund Investment Criteria:

  • Early revenue stage companies
  • Transformative technology
  • Modest valuations and high growth


Stage of Investment

In order to take full advantage of our expertise in the healthcare sector, we focus on early and growth stage opportunities where BMP can act as an investor and partner to management teams. We seek companies that have existing customers and products or services operating in markets where we have a high degree of confidence. On occasion we will invest in deals led by other high quality private investors who seek our active involvement to enhance a businesses’ growth strategy.

Preferred Investment Size

Typical first round investments range from $250,000 to $3,000,000, with follow-on financings often doubling the original capital commitment. In select cases, we have made initial investments of as little as $100,000 with the expectation that we will significantly increase our investment through later commitments.

Our Firm – What We Look For

US healthcare spending is projected to grow at a compound annual growth rate of 5.6%, 21% higher than the projected U.S. GDP growth. Pharmaceutical companies increasingly are looking for new approaches and toolsets in drug development. Pharma R&D spending has outpaced FDA drug approvals, showing a market need for innovation around how to aid the drug development process.

Information technology advances will affect all areas of pre-clinical and clinical trials, including patient recruitment and selection, data capture, data analysis and post market surveillance. Adverse event detection, reporting and analysis will also be impacted. Superior outcomes characterization will yield more effective treatment protocols and clinical pathways. Soft tissue imaging, expert remote diagnosis, remote treatment, remote second opinion and data-based case management will all be advanced to control costs and improve outcomes. Our specific areas of interest include:

  • B2B business models selling to providers, payors, and biopharma
  • “Picks and shovels” businesses supporting the research and drug development process
  • Health data integrations and analytics
  • Value-based care enablement
  • Innovative care models
  • Precision medicine advancement